Oseltamivir Market Size Estimated to Reach $744.3 Billion by 2027

Oseltamivir’s Market | IndustryARC
Elevation in the Spread of Contagions Post-COVID-19 Is Anticipated To Boost Oseltamivir Market

Oseltamivir Market size is estimated to reach $744.3 billion by 2027, growing at a CAGR of 3.1% during the forecast period 2022-2027. Oseltamivir falls under the category of antiviral medication of sialic acid analog which is extensively used to cure cases of flu-like influenza A and influenza B. These are transmissible viral contagions that leads to respiratory complications such as fever, nausea, gastroenteritis, cough, pain in the throat, tiredness. In maximum cases, symptoms are resolvable through antiviral drugs, but the persistence of the flu may lead to serious health problems which can be life-threatening. Neuraminidase inhibitors such as Tamiflu and Relenza impede the spread of infections like Influenza A and B by simply stalling the replication process. Heightening respiratory complications along with the geriatric faction of the population increased flows of hard cash into research and development of new drugs, and rising cognizance among the population are factors set to drive the growth of the Oseltamivir Industry for the period 2022-2027.

Oseltamivir Market Segment Analysis – By Treatment

The Oseltamivir Market based on the treatment type can be further segmented into Influenza A and Influenza B. The Influenza A segment held the largest share of the overall market in 2021. The growth is owing to augmenting prevalence of cases inflicted by influenza A. Its spread is not only limited to human beings like influenza B. Its prevalence is quite common in animals and birds like pigs, horses, ducks, chickens, and many more. On another hand, it is a more serious form as it leads to worse symptoms as compared to influenza B.

Moreover, the Influenza A segment is estimated to be the fastest growing with a CAGR of 3.7% over the forecast period 2022-2027. This growth is owing to proliferating health consciousness among people, more focus upon research and development of curing drugs by pharma companies and research institutions. Furthermore, as per US CDC, influenza which has been attributed to viruses had a prevalence of 1% in the week ending November 20, 2021.

For More Information About Oseltamivir Market @


Report Price: $ 4500 (Single User License)

Oseltamivir Market Segment Analysis – By Distribution Channel

The Oseltamivir Market based on Distribution Channel can be further segmented into hospitals, Retail Pharmacies, Drug Stores, Local medical Stores, Online Platforms. The retail pharmacy segment held the largest share in 2021. The growth is owing to factors such as the board presence of retail pharmacy stores even in pastoral areas. On another hand, maximum drugs in such stores are available without any prior prescription from a medical practitioner.

Moreover, online is estimated to be the fastest-growing segment with a CAGR of 4.1% over the forecast period 2022-2027. This growth is owing to speedy digitalization ensuing in an improved online setup. Making online purchases instead of visiting drug stores in person encompasses a surfeit of benefits such as convenient purchase, saving time, the general presence of digital platforms as their delivery services are omnipresent. Furthermore, Fluvir, a 75 MG capsule of Oseltamivir is available on a digital platform named- Tata 1Mg is available for INR 394, against the MRP of INR 539. Strategies such as cash-backs, discount coupons, and subscriptions are the plausible factors that can fuel the segment growth.

Oseltamivir Market Segment Analysis-By Geography

The Oseltamivir Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 35% of the overall market in 2021. The growth in this segment is owing to the factors such as health-aware population, state-of-the-art healthcare infrastructures such as hospitals and research laboratories with world-class facilities in the US and Canada, a widespread network of retail pharmacies and drug stores. Furthermore, the FY 2022 budget proposes $131.8billion in discretionary budget authority and $1.5 trillion in mandatory funding within the US.

However, Asia-Pacific is anticipated to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to the colossal population in Asian countries like India and China leading to immersive spread in contagions, prospering economies allowing governments to invest an innumerable amount of riches into research and development of novel drugs and refining the already existing network of hospitals and clinics.

Oseltamivir Market Drivers

Elevation in the spread of contagions post-COVID-19 is Anticipated to Boost Product Demand

There has been an ascension in several communicable infectious maladies around the globe post-COVID-19. According to the report as lockdowns are coming to an end and people are coming back to their normal life, influenza cases may shoot up precipitously as human-to-human interactions are happening again. Moreover, the elderly population is on the rise, and the dwindling immunities of old people are more prone to respiratory sicknesses which can increase the overall demand for antiviral medications. According to a US clinical report out of 265,492 tested specimens out of total positive cases, 74.4% were found positive with Influenza A, whereas 25.6% with B. this shows us how influenza A cases are dominating in terms of total infections.

Ascending flows of riches in research is Expected to Boost Product Demand

Post COVID-19 there has been a massive shift in general thinking of people regarding health. People’s attitudes are changing from treatment to prevention of the disease, and their overall awareness regarding such drugs is spiking day after day. On the other hand, Governments are the globe are allocating more funds to refine the existing and are building new healthcare infrastructure. By the end of 2028 Us healthcare spending is anticipated to reach 20% of their GDP (around $6.2 trillion). All these aforementioned factors are expected to fuel the growth of the oseltamivir market.

Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=501917

Oseltamivir Market Challenges

Side-effect associated with oseltamivir is Anticipated to Hamper Market Growth

One factor which is anticipated to reduce the growth of the aforesaid market is the side effects allied with the use of such antiviral medications. Oseltamivir intake can lead to several health complications such as nausea, gastroenteritis, pain in the stomach. In a few cases, it may give rise to serious health complications such as heart attack, severe liver maladies, kidney problems that can be life-threatening. These drawbacks can strangle the growth of the overall market.

Oseltamivir Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Oseltamivir Market. Key companies of this market are-


Nagar Medico

NATCO Pharma Limited


Triveni Chemical

Lotus International

Hetero Healthcare

F. Hoffmann-La Roche Ltd.

Alembic Pharmaceuticals

Zydus Cadila

Recent Developments

On November 12, 2021, an antiviral medicine “Oselavir” has been launched into the Chinese market by India-based pharmaceutical firm Hetero healthcare and Shenzhen Beimei a Chinese player. Both these firms are in a partnership with each other for a long time. It will be made available in China with the dosage form of 12.5 ml :75 mg for oral suspension. Additionally, the dosage can be given to children >2 weeks, apart from adults and adolescents.

On June 19, 2021, a few cases of influenza A (H1N1) have been found at a detention center located at the Texas border. The researcher claimed that the aforementioned influenza exhibit properties which are resisting the effects of the antiviral drug “Oseltamivir.” A total of four cases were reported, which hemagglutinin that belong to a subclade that may enable viral escape from pre-existing immunity. Further, the virologists have reported concerns pertaining to the same.

On February 15, 2021, “Lupin Pharmaceuticals and AuroMedics Pharma” Baltimore and east Windsor-based branches of two Indian pharmaceutical companies recalled several anti-viral drugs from the US market ascribing to impurities. The drug-maker has recalled around 46,749 bottles of the anti-viral medication- Oseltamivir for oral suspension. The product was manufacturer in the Aurangabad- Maharashtra Facility within India.

Key Takeaways:

Geographically, the North American Oseltamivir Market accounted for the highest revenue share in 2021. However, Asia-Pacific is poised to dominate the market over the period 2022-2027.

The growing prevalence of communicable contagions is said to be the preeminent driver driving the growth of the Oseltamivir Market. However, many health-linked side effects such as insomnia are said to reduce the market growth.

Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Oseltamivir Market report.

Relevant Links:

Generic Drugs Market


For more Lifesciences and Healthcare Market reports, please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Venkat Reddy
Email: Send Email
Phone: (+1) 970-236-3677
City: Hyderabad
Country: India
Website: https://www.industryarc.com/